Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
27
02
2019
revised:
14
07
2019
accepted:
20
08
2019
entrez:
20
12
2019
pubmed:
20
12
2019
medline:
20
12
2019
Statut:
epublish
Résumé
iPrevent is an online breast cancer (BC) risk management decision support tool. It uses an internal switching algorithm, based on a woman's risk factor data, to estimate her absolute BC risk using either the International Breast Cancer Intervention Study (IBIS) version 7.02, or Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm version 3 models, and then provides tailored risk management information. This study assessed the accuracy of the 10-year risk estimates using prospective data. iPrevent-assigned 10-year invasive BC risk was calculated for 15 732 women aged 20-70 years and without BC at recruitment to the Prospective Family Study Cohort. Calibration, the ratio of the expected (E) number of BCs to the observed (O) number and discriminatory accuracy were assessed. During the 10 years of follow-up, 619 women (3.9%) developed BC compared with 702 expected (E/O = 1.13; 95% confidence interval [CI] =1.05 to 1.23). For women younger than 50 years, 50 years and older, and For 10-year BC risk, iPrevent had good discriminatory accuracy overall and was well calibrated for women aged younger than 50 years. Calibration may be improved in the future by incorporating IBIS version 8.0b.
Sections du résumé
BACKGROUND
BACKGROUND
iPrevent is an online breast cancer (BC) risk management decision support tool. It uses an internal switching algorithm, based on a woman's risk factor data, to estimate her absolute BC risk using either the International Breast Cancer Intervention Study (IBIS) version 7.02, or Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm version 3 models, and then provides tailored risk management information. This study assessed the accuracy of the 10-year risk estimates using prospective data.
METHODS
METHODS
iPrevent-assigned 10-year invasive BC risk was calculated for 15 732 women aged 20-70 years and without BC at recruitment to the Prospective Family Study Cohort. Calibration, the ratio of the expected (E) number of BCs to the observed (O) number and discriminatory accuracy were assessed.
RESULTS
RESULTS
During the 10 years of follow-up, 619 women (3.9%) developed BC compared with 702 expected (E/O = 1.13; 95% confidence interval [CI] =1.05 to 1.23). For women younger than 50 years, 50 years and older, and
CONCLUSIONS
CONCLUSIONS
For 10-year BC risk, iPrevent had good discriminatory accuracy overall and was well calibrated for women aged younger than 50 years. Calibration may be improved in the future by incorporating IBIS version 8.0b.
Identifiants
pubmed: 31853515
doi: 10.1093/jncics/pkz066
pii: pkz066
pmc: PMC6901082
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkz066Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press.
Références
JAMA Oncol. 2018 Apr 1;4(4):476-482
pubmed: 29346471
Breast Cancer Res. 2018 Nov 3;20(1):132
pubmed: 30390716
J Natl Cancer Inst. 2019 Mar 1;111(3):331-334
pubmed: 30496449
Carcinogenesis. 2008 Jul;29(7):1367-72
pubmed: 18566018
Breast Cancer Res Treat. 2016 Feb;156(1):171-82
pubmed: 26909793
Genet Med. 2019 Aug;21(8):1708-1718
pubmed: 30643217
Implement Sci. 2018 Aug 20;13(1):114
pubmed: 30126421
Aust J Prim Health. 2016;22(3):255-261
pubmed: 25705982
J Natl Cancer Inst. 1989 Dec 20;81(24):1879-86
pubmed: 2593165
Cancer Prev Res (Phila). 2018 Jan;11(1):38-43
pubmed: 29061559
PLoS Med. 2018 Sep 4;15(9):e1002644
pubmed: 30180161
Breast Cancer Res. 2004;6(4):R375-89
pubmed: 15217505
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Lancet Oncol. 2019 Apr;20(4):504-517
pubmed: 30799262
J Clin Epidemiol. 2016 Jun;74:167-76
pubmed: 26772608
Ann Intern Med. 2008 Mar 4;148(5):337-47
pubmed: 18316752
Lancet. 2013 May 25;381(9880):1827-34
pubmed: 23639488
Am J Hum Genet. 1998 Jan;62(1):145-58
pubmed: 9443863
J Natl Cancer Inst. 2001 Mar 7;93(5):358-66
pubmed: 11238697
J Med Genet. 2003 Nov;40(11):807-14
pubmed: 14627668
Breast Cancer Res Treat. 2017 Jul;164(2):263-284
pubmed: 28444533
Breast. 2019 Feb;43:39-47
pubmed: 30445378
Int J Epidemiol. 2016 Jun;45(3):683-92
pubmed: 26174520
Lancet. 2008 Aug 23;372(9639):608-10
pubmed: 18722851
JAMA Oncol. 2018 Sep 1;4(9):e180174
pubmed: 29621362
Br J Cancer. 2008 Apr 22;98(8):1457-66
pubmed: 18349832
Fam Cancer. 2005;4(2):105-13
pubmed: 15951960
Epidemiology. 2010 Jan;21(1):128-38
pubmed: 20010215
Genet Med. 2016 Dec;18(12):1190-1198
pubmed: 27464310
JMIR Form Res. 2018 Nov 07;2(2):e24
pubmed: 30684421
Breast. 2014 Oct;23(5):644-50
pubmed: 24998452